3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
4
Phase 2
3
Phase 1/2
3
Phase EARLY_PHASE1
1
Phase 3
1
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
10
Multiple Myeloma
8
Leukemia
6
Lung Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Burkitt Lymphoma
3
Recurrence
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Neoplasms, Plasma Cell
2
Lymphoma
2
Leukemia, T-Cell
2
Waldenstrom Macroglobulinemia
1
Vomiting
1
Uterine Cervical Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Mouth Neoplasms
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell
1
Leukemia, Myeloid, Acute
1
Fatigue
1
Congenital Abnormalities
1
Breast Neoplasms
1
Breast Carcinoma In Situ
1
Brain Neoplasms
1
Interventions
Rituximab
2
loncastuximab tesirine
1
etoposide phosphate
1
blinatumomab
1
Tubercidin
1
Immunotherapy, Adoptive
1
Ifosfamide
1
Etoposide
1
Dexamethasone
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Lymphoma, B-Cell
×
Dexamethasone
×
Clear all
NCT05991388
2026-02-20
Glo-BNHL
University of Birmingham
Phase 2/3
Recruiting
210 enrolled